Armbrecht Ana Maria, Findlay Catherine, Aspinall Peter Alan, Hill Adrian Robert, Dhillon Baljean
Princess Alexandra Eye Pavilion, Edinburgh, The Royal Infirmary of Edinburgh, Scotland, United Kingdom.
J Cataract Refract Surg. 2003 Apr;29(4):686-93. doi: 10.1016/s0886-3350(02)01650-4.
To determine whether patients with age-related macular degeneration (ARMD) benefit from cataract surgery and to assess the risk of progression of preexisting maculopathy 4 and 12 months postoperatively.
Princess Alexandra Eye Pavilion, Royal Infirmary of Edinburgh, Edinburgh, Scotland.
Two groups of patients were evaluated prospectively. The study group comprised patients with ARMD scheduled to have cataract surgery (n = 40). The control group comprised patients with ARMD not having cataract surgery (n = 43). Patients were assessed at baseline (preoperatively) and 4 and 12 months postoperatively. Assessment included visual function tests and quality of life (QoL) measures. The mean values for each item tested were obtained for each group at each visit, and comparisons between visits were done using the Wilcoxon signed rank test.
There were significant benefits of cataract surgery in terms of visual function and QoL measures at 4 and 12 months. There was no increased risk of progression of maculopathy in the study group. There were no significant differences in the items tested in the control group.
One year postoperatively, QoL benefits were maintained in the study group and there was no increased risk of progression of maculopathy in patients with mild and moderate degrees of ARMD. Larger numbers of patients must be assessed prospectively for longer periods to determine the relative risk of progression of different stages of ARMD after cataract surgery.
确定年龄相关性黄斑变性(ARMD)患者是否能从白内障手术中获益,并评估术前存在的黄斑病变在术后4个月和12个月进展的风险。
苏格兰爱丁堡皇家医院亚历山德拉公主眼科中心。
对两组患者进行前瞻性评估。研究组包括计划接受白内障手术的ARMD患者(n = 40)。对照组包括未接受白内障手术的ARMD患者(n = 43)。在基线(术前)以及术后4个月和12个月对患者进行评估。评估包括视觉功能测试和生活质量(QoL)测量。每次访视时获取每组每项测试项目的平均值,并使用Wilcoxon符号秩检验进行访视间比较。
在术后4个月和12个月时,白内障手术在视觉功能和QoL测量方面有显著益处。研究组黄斑病变进展风险未增加。对照组测试项目无显著差异。
术后一年,研究组维持了生活质量益处,轻度和中度ARMD患者黄斑病变进展风险未增加。必须对更多患者进行更长时间的前瞻性评估,以确定白内障手术后不同阶段ARMD进展的相对风险。